Established in 1992, Transcend Therapeutics is a clinical-stage, neuroscience-focused company that develops psychoactive medicines for neuropsychiatric diseases caused by oxidative stress and tissue damage. Their lead product has shown significant benefits to over 85% of patients with PTSD and depression, and they plan to expand into other indications. The company's leadership team includes scientists with federal funding for clinical psychedelic research and drug development executives with pivotal contributions to 13 FDA approvals. Backed by AlleyCorp, a venture capital fund that has founded some of the most transformative companies in New York, Transcend Therapeutics has pledged 10% of founding shares towards nonprofits focused on scientific research and patient access.